Nucleic-Acid Delivery Using Lipid Nanocapsules


Autoria(s): Lagarce, Frédéric; Passirani-Malleret, Catherine
Contribuinte(s)

Micro et nanomédecines biomimétiques (MINT) ; Université d'Angers (UA) - Institut National de la Santé et de la Recherche Médicale (INSERM)

Data(s)

2016

Resumo

International audience

<p>Lipid nanocapsules (LNCs) were designed more than 15 years ago to deliver lipophilic drugs to cells with non toxic excipients by mimicking lipoproteins. During the last 5 years these promising nanocarriers were re-designed to deliver nucleic acids to cancer cells. This short review sums up the features of LNCs and describes how DNAs or RNAs can be associated or encapsulated in these lipid carriers. The results of transfection effects on cells in vitro or in vivo are also presented. These new therapeutic strategies have been mainly proposed for glioma and melanoma treatment because these cancers are characterized by multiple acquired resistances, which can be reversed by DNA transfection or siRNA interference as it is discussed in this paper. In conclusion, LNCs are very good candidates to deliver nucleic acids to cells in the course of anti-cancer therapies.</p>

Identificador

hal-01392476

https://hal.archives-ouvertes.fr/hal-01392476

DOI : 10.2174/1389201017666160401145206

OKINA : ua14715

Idioma(s)

en

Publicador

HAL CCSD

Relação

info:eu-repo/semantics/altIdentifier/doi/10.2174/1389201017666160401145206

Fonte

ISSN: 1873-4316

Current Pharmaceutical Biotechnology

https://hal.archives-ouvertes.fr/hal-01392476

Current Pharmaceutical Biotechnology , 2016, 17 (8), pp.723-7. <http://www.eurekaselect.com/140908/article>. <10.2174/1389201017666160401145206>

http://www.eurekaselect.com/140908/article

Palavras-Chave #Cancer therapy #DNA #Lipid nanocapsules #nanomedicine #non-viral vectors #RNA #[SDV] Life Sciences [q-bio]
Tipo

info:eu-repo/semantics/article

Journal articles